The Molbio team embraces tradition with Dussehra festivities.
Through continuous research and innovation, we focus on developing technologies that enhance access to timely and accurate testing. Collaboration and knowledge-sharing remain central to our approach as we work closely with healthcare professionals to improve diagnostic capabilities and strengthen healthcare delivery. |
Image description will come here on hover. Image description will come here on hover.
Image description will come here on hover. Image description will come here on hover.
Image description will come here on hover. Image description will come here on hover.
Image description will come here on hover. Image description will come here on hover.
The Molbio team embraces tradition with Dussehra festivities.
Passion met to play at The Molbio Premier League!
The excitement of an adventure at one of our picnics!
The guiding star at Molbio has always been ‘Team Values’.
We learn, grow and celebrate at team dinners!
Connect with us
Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
© All Rights Reserved
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA. THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED.
Investors should read the Draft Red Herring Prospectus and seek professional advice before taking any action.
IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.
The following disclaimer applies to the draft red herring prospectus of Molbio Diagnostics Limited (the “Company”) dated August 22, 2025 (the “Draft Red Herring Prospectus”) filed with the Securities and Exchange Board of India (“SEBI”) and hosted on this website in connection with the initial public offering of the equity shares (“Equity Shares”) of the Company (the “Offer”). You are advised to read the following notice carefully before accessing the Draft Red Herring Prospectus. In accessing the Draft Red Herring Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.
Access to the Draft Red Herring Prospectus does not constitute a recommendation by the Company, the members of the Syndicate (as defined in the Draft Red Herring Prospectus) or any of their respective affiliates or any other person to subscribe to the Equity Shares offered in the Offer.
The Draft Red Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Draft Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. The contents of the Draft Red Herring Prospectus is for your information only, and you acknowledge that access to the Draft Red Herring Prospectus is intended for use by you only and you agree not to forward the Draft Red Herring Prospectus on to any other person, internal or external to your company, in whole or in part, or otherwise provide access via e-mail or otherwise to any person. Any person into whose possession the DRHP comes is required to inform himself or herself about and to observe any such restrictions. BRLMs and/or its affiliates or their respective directors, officers and employees are not soliciting any action based on any of the information contained on this website, including the DRHP, and such information should not be construed as an offer, or invitation or offer to sell or the solicitation of any offer to buy or subscribe for or purchase any security. No part of the contents of the Draft Red Herring Prospectus shall be copied or duplicated in any form by any means or redistributed.
The Draft Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. Our Company has taken all necessary steps to ensure that the contents of the Draft Red Herring Prospectus as appearing on this website are identical to the Draft Red Herring Prospectus filed with the SEBI. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neither the Company nor the BRLMs any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.
The Draft Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction and is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company or any of its affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“U.S. Securities Act”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in ‘offshore transactions’ in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.
Any person into whose possession the Draft Red Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions. Neither the Company, BRLMs nor any of its affiliates is soliciting any action based on the Draft Red Herring Prospectus, and it should not be construed as an offer to sell or the solicitation of an offer to buy any securities. Potential investors should not rely on the Draft Red Herring Prospectus for any investment decision.
Any decision on whether to invest in the equity shares described in the Draft Red Herring Prospectus may only be made after a red herring prospectus has been filed with the Registrar of Companies, Goa, Daman and Diu at Panaji and the SEBI and must be made solely on the basis of such red herring prospectus, as there may be material changes in the red herring prospectus compared to the Draft Red Herring Prospectus. Invitations to subscribe to or purchase the equity shares in the Offer will be made only pursuant to the red herring prospectus if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises the red herring prospectus and the preliminary international wrap for the Offer, if the recipient is outside India. No person outside India is eligible to Bid for equity shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which shall contain the selling restrictions for the Offer outside India.
Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled “Risk Factors” of the red herring prospectus, when available.
Neither the Company, BRLMs, nor any of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Company and its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Draft Red Herring Prospectus beyond the date of the Draft Red Herring Prospectus. The information contained in the Draft Red Herring Prospectus may not be updated since its original publication date and may not reflect the latest updates. The Company and its affiliates will not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company, any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.
If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
To access this information, you must confirm by pressing on the button marked “I Confirm” that, at the time of access you are located and resident in India. If you cannot make this confirmation, you must press the button marked “I Do Not Confirm”.
The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.
This will close in 0 seconds
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA. THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED.
Investors should read the Draft Red Herring Prospectus and seek professional advice before taking any action.
IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.
The following disclaimer applies to the draft red herring prospectus of Molbio Diagnostics Limited (the “Company”) dated August 22, 2025 (the “Draft Red Herring Prospectus”) filed with the Securities and Exchange Board of India (“SEBI”) and hosted on this website in connection with the initial public offering of the equity shares (“Equity Shares”) of the Company (the “Offer”). You are advised to read the following notice carefully before accessing the Draft Red Herring Prospectus. In accessing the Draft Red Herring Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.
Access to the Draft Red Herring Prospectus does not constitute a recommendation by the Company, the members of the Syndicate (as defined in the Draft Red Herring Prospectus) or any of their respective affiliates or any other person to subscribe to the Equity Shares offered in the Offer.
The Draft Red Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Draft Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. The contents of the Draft Red Herring Prospectus is for your information only, and you acknowledge that access to the Draft Red Herring Prospectus is intended for use by you only and you agree not to forward the Draft Red Herring Prospectus on to any other person, internal or external to your company, in whole or in part, or otherwise provide access via e-mail or otherwise to any person. Any person into whose possession the DRHP comes is required to inform himself or herself about and to observe any such restrictions. BRLMs and/or its affiliates or their respective directors, officers and employees are not soliciting any action based on any of the information contained on this website, including the DRHP, and such information should not be construed as an offer, or invitation or offer to sell or the solicitation of any offer to buy or subscribe for or purchase any security. No part of the contents of the Draft Red Herring Prospectus shall be copied or duplicated in any form by any means or redistributed.
The Draft Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. Our Company has taken all necessary steps to ensure that the contents of the Draft Red Herring Prospectus as appearing on this website are identical to the Draft Red Herring Prospectus filed with the SEBI. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neither the Company nor the BRLMs any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.
The Draft Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction and is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company or any of its affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“U.S. Securities Act”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in ‘offshore transactions’ in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.
Any person into whose possession the Draft Red Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions. Neither the Company, BRLMs nor any of its affiliates is soliciting any action based on the Draft Red Herring Prospectus, and it should not be construed as an offer to sell or the solicitation of an offer to buy any securities. Potential investors should not rely on the Draft Red Herring Prospectus for any investment decision.
Any decision on whether to invest in the equity shares described in the Draft Red Herring Prospectus may only be made after a red herring prospectus has been filed with the Registrar of Companies, Goa, Daman and Diu at Panaji and the SEBI and must be made solely on the basis of such red herring prospectus, as there may be material changes in the red herring prospectus compared to the Draft Red Herring Prospectus. Invitations to subscribe to or purchase the equity shares in the Offer will be made only pursuant to the red herring prospectus if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises the red herring prospectus and the preliminary international wrap for the Offer, if the recipient is outside India. No person outside India is eligible to Bid for equity shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which shall contain the selling restrictions for the Offer outside India.
Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled “Risk Factors” of the red herring prospectus, when available.
Neither the Company, BRLMs, nor any of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Company and its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Draft Red Herring Prospectus beyond the date of the Draft Red Herring Prospectus. The information contained in the Draft Red Herring Prospectus may not be updated since its original publication date and may not reflect the latest updates. The Company and its affiliates will not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company, any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.
If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
To access this information, you must confirm by pressing on the button marked “I Confirm” that, at the time of access you are located and resident in India. If you cannot make this confirmation, you must press the button marked “I Do Not Confirm”.
The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.
This will close in 0 seconds
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA. THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED.
Investors should read the Draft Red Herring Prospectus and seek professional advice before taking any action.
IMPORTANT: You must read and agree with the terms and conditions of the following disclaimer before continuing.
The following disclaimer applies to the draft red herring prospectus of Molbio Diagnostics Limited (the “Company”) dated August 22, 2025 (the “Draft Red Herring Prospectus”) filed with the Securities and Exchange Board of India (“SEBI”) and hosted on this website in connection with the initial public offering of the equity shares (“Equity Shares”) of the Company (the “Offer”). You are advised to read the following notice carefully before accessing the Draft Red Herring Prospectus. In accessing the Draft Red Herring Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.
Access to the Draft Red Herring Prospectus does not constitute a recommendation by the Company, the members of the Syndicate (as defined in the Draft Red Herring Prospectus) or any of their respective affiliates or any other person to subscribe to the Equity Shares offered in the Offer.
The Draft Red Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Draft Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. The contents of the Draft Red Herring Prospectus is for your information only, and you acknowledge that access to the Draft Red Herring Prospectus is intended for use by you only and you agree not to forward the Draft Red Herring Prospectus on to any other person, internal or external to your company, in whole or in part, or otherwise provide access via e-mail or otherwise to any person. Any person into whose possession the DRHP comes is required to inform himself or herself about and to observe any such restrictions. BRLMs and/or its affiliates or their respective directors, officers and employees are not soliciting any action based on any of the information contained on this website, including the DRHP, and such information should not be construed as an offer, or invitation or offer to sell or the solicitation of any offer to buy or subscribe for or purchase any security. No part of the contents of the Draft Red Herring Prospectus shall be copied or duplicated in any form by any means or redistributed.
The Draft Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended. Our Company has taken all necessary steps to ensure that the contents of the Draft Red Herring Prospectus as appearing on this website are identical to the Draft Red Herring Prospectus filed with the SEBI. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neither the Company nor the BRLMs any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.
The Draft Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction and is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company or any of its affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“U.S. Securities Act”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in ‘offshore transactions’ in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.
Any person into whose possession the Draft Red Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions. Neither the Company, BRLMs nor any of its affiliates is soliciting any action based on the Draft Red Herring Prospectus, and it should not be construed as an offer to sell or the solicitation of an offer to buy any securities. Potential investors should not rely on the Draft Red Herring Prospectus for any investment decision.
Any decision on whether to invest in the equity shares described in the Draft Red Herring Prospectus may only be made after a red herring prospectus has been filed with the Registrar of Companies, Goa, Daman and Diu at Panaji and the SEBI and must be made solely on the basis of such red herring prospectus, as there may be material changes in the red herring prospectus compared to the Draft Red Herring Prospectus. Invitations to subscribe to or purchase the equity shares in the Offer will be made only pursuant to the red herring prospectus if the recipient is in India or the preliminary offering memorandum for the Offer, which comprises the red herring prospectus and the preliminary international wrap for the Offer, if the recipient is outside India. No person outside India is eligible to Bid for equity shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which shall contain the selling restrictions for the Offer outside India.
Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled “Risk Factors” of the red herring prospectus, when available.
Neither the Company, BRLMs, nor any of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Company and its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Draft Red Herring Prospectus beyond the date of the Draft Red Herring Prospectus. The information contained in the Draft Red Herring Prospectus may not be updated since its original publication date and may not reflect the latest updates. The Company and its affiliates will not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company, any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.
If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
To access this information, you must confirm by pressing on the button marked “I Confirm” that, at the time of access you are located and resident in India. If you cannot make this confirmation, you must press the button marked “I Do Not Confirm”.
The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.
This will close in 0 seconds
Sriram Natarajan is an Executive Director and the Chief Executive Officer of Molbio Diagnostics.
At Molbio Diagnostics, he is responsible for overseeing Business Management and overall Strategy. He holds a Bachelor’s Degree in Science (Botany) from the University of Delhi, a Master’s Degree in Science (Plant Physiology)from Tamil Nadu Agricultural University, Coimbatore, and a Master of Philosophy Degree in Botany from the University of Delhi. He has 35 years of experience in developing, manufacturing, and marketing diagnostic devices and kits in domestic and international markets, for both private and public sector enterprises.
He was one of the founders of Tulip Diagnostics Private Limited, where he previously served as a Director on the Board. He has been awarded the Healthcare Award 2021 by The Economic Times for outstanding research in healthcare – Covid-19 (along with Dr. Chandrasekhar Bhaskaran Nair), and the Tech Leader 2023 Award by Future Ready Tech Events.
He was named one of India’s Top 200 Self-Made Entrepreneurs of the Millennia, 2024 by IDFC First Bank.
Dr. Chandrasekhar Bhaskaran Nair is an Executive Director and the Chief Technology Officer of Molbio Diagnostics. At Molbio, he is responsible for overseeing Research & Development. He holds a Bachelor’s Degree in Engineering (Chemistry) from Birla Institute of Technology and Science, Pilani, Rajasthan, a Master’s Degree in Engineering (Chemistry) from Birla Institute of Technology and Science, Pilani, Rajasthan, and a Doctor of Philosophy degree from the School of Bio Sciences and Technology, VIT University, Vellore, Tamil Nadu.
He has 33 years of experience in translational Research & Development, leading multidisciplinary teams to develop various products. He previously served as Head – Engineering and Computer Sciences with Vittal Mallya Scientific Research Foundation. He has been awarded the Infosys Prize 2021 in Engineering and Computer Science by the Infosys Science Foundation, and the Healthcare Award 2021 by The Economic Times for outstanding research in healthcare – Covid-19 (along with Sriram Natarajan).
Sangeetha Sriram is an Executive Director and the Director of Operations of Molbio Diagnostics. At Molbio, she is responsible for overseeing Operations and Administration
She holds a Bachelor’s Degree in Science from Sri Venkateswara University, Tirupati, Andhra Pradesh, and a Master’s Degree in Science (Botany) from the University of Delhi. She has five years of experience in the Diagnostics Sector.
Amol Narayan Lone is the President – Finance & Accounts and Chief Financial Officer of Molbio Diagnostics. He has been associated with Molbio Diagnostics since June 4, 2024. At Molbio Diagnostics, he is responsible for Finance & Accounts.
He holds a Bachelor’s Degree in Commerce from B.Y.K. College of Commerce, Nasik, University of Pune, and a Master’s Degree in Business Administration from the Institute of Chartered Financial Analysts of India University, Tripura, and is an Associate Member of the Institute of Chartered Accountants of India.
He has 18 years of experience in Finance & Accounts. Before his association with Molbio Diagnostics, he previously worked with Henkel Adhesives Technologies India Private Limited, Watson Pharma Private Limited, and served as Vice President – Finance with Fermenta Biotech Limited, among others, and has handled functions such as Finance & Accounts.
Darshan has been associated with Molbio since July 24, 2024. At Molbio, he is responsible for legal and secretarial matters and holds a bachelor’s degree in commerce from Goa University, a bachelor’s degree in law from Goa University, a diploma in cyber law from Government Law College, Mumbai, and a Professional Programme Certificate from the Institute of Company Secretaries of India. He is a Fellow Member of the Institute of Company Secretaries of India and carries eight years of experience in the manufacturing sector. Before his association with Molbio Diagnostics, he previously served as assistant company secretary at Smartlink Holdings Limited, company secretary at Digisol Systems Limited, company secretary and compliance officer at Chowgule Steamships Limited, and manager (company secretary and statutory compliance) at Goa Glass Fibre Limited, and has handled functions such as secretarial matters. He is also the Chairman of the Managing Committee of the Goa Chapter of the WIRC-ICSI.
Shiva Sriram is the President – Business Development of Molbio Diagnostics. He has been associated with the company since April 1, 2018. At Molbio, he is responsible for Business Development.
He holds a Bachelor’s Degree in Science (Biochemistry) from the University of Delhi and a Master’s Degree in Science (Biochemical Engineering) from University College London, United Kingdom. He has seven years of experience in the diagnostics sector.
Dr. Kuldeep Singh Sachdeva is the President – Strategy and Project Management and Chief Medical Officer of Molbio Diagnostics. He has been associated with Molbio Diagnostics since January 1, 2024. At Molbio, he is responsible for Strategy and Project Management. He holds a Bachelor’s Degree in Medicine and Surgery from the University of Delhi, a Post-Graduate Diploma in Hospital and Health Management from Indira Gandhi National Open University, New Delhi, a Post-Graduate Diploma in Disaster Preparedness and Rehabilitation from Guru Gobind Singh Indraprastha University, Delhi, and a Master’s Degree in Business Administration (Healthcare Administration) from the University of Delhi.
He started his career as a Medical Officer in the Central Health Service in 1988 and retired from the Department of Health and Family Welfare, Ministry of Health and Family Welfare, in 2021. Before his association with Molbio Diagnostics, he previously served as Deputy Director General with the National AIDS Control Organisation, New Delhi, and Regional Director of The Union South-East Asia Office of the International Union Against Tuberculosis and Lung Disease.
Sarah Sarika Frias Oliviera Fernandes is the Head of Human Resource and Administration (General Manager) at Molbio Diagnostics. She has been associated with Molbio since May 21, 2025 and is responsible for overseeing human resources and administration. She holds a bachelor’s degree in science from Goa University, a master’s degree in science from Goa University, Panaji and a master’s degree in business administration from the Indian Institute of Advanced Management Training and Research.
She has 18 years of experience in human resource management in the manufacturing sector. Before her association with Molbio, she was previously associated with Syngenta India Limited, and has previously served as the Head of Human Resources with IFB Industries Limited and Manager, Talent Management with Deccan Fine Chemicals (India) Private Limited.
Sumit Mitra is the President – International Sales of Molbio Diagnostics. He has been associated with the company since 2013.
At Molbio Diagnostics, he is responsible for Sales. He holds a Bachelor’s Degree in Science from North-Eastern Hill University, Shillong, and a Master’s Degree in Science (Biochemistry) from North-Eastern Hill University, Shillong.
He has 21 years of experience in the Diagnostics Sector. Before his association with Molbio Diagnostics, he previously served as Marketing Manager with Tulip Diagnostics Private Limited and has handled functions such as Sales and Marketing.
Indraneil Borkakoty is the Vice President – Investor Relations and Mergers & Acquisitions of Molbio Diagnostics. He has been associated with Molbio Diagnostics since May 15, 2024. At Molbio Diagnostics, he is responsible for Investor Relations and Mergers & Acquisitions. He holds a Bachelor’s Degree in Arts from the University of Delhi and a Postgraduate Diploma in Management from the International Management Institute, New Delhi.
Before his association with Molbio Diagnostics, he previously served as Executive Director with Kotak Mahindra Capital Company Limited, Managing Director – Investment Banking Division with Nomura Financial Advisory and Securities (India) Private Limited, Managing Director with IDFC Securities Limited, and Managing Director – Investment Banking Department with Jefferies India Private Limited.
Reeti Desai Hobson is the Vice President – Global Health Programs and Partnerships at Molbio Diagnostics. She has been associated with the organisation since July 22, 2024.
At Molbio, she is responsible for global business development. She holds a bachelor’s degree in science with a major in molecular biology from the University of California, a master’s degree in public health from New York University, and a professional certificate course from University of California, San Diego in clinical trials, design and management.
Before her association with Molbio she has previously associated with ICF Macro, Inc. and USAID (United States Agency for International Development), among various other organisations.
Dr. Arun Kumar Jha is an Independent Director on the Board of Molbio Diagnostics. He holds a bachelor’s degree in arts (economics) from the University of Delhi, a bachelor’s degree in law from the University of Delhi, a master’s degree in arts (economics) from Himachal Pradesh University, a master’s degree in science (finance) from the University of Strathclyde, and a doctor of philosophy (economics) degree from Arunachal University of Studies, Arunachal Pradesh.
He is a retired officer of the Indian Economic Service with 36 years of experience in the public sector. He previously served as principal adviser in the Department of Agriculture and Farmers Welfare, Ministry of Agriculture and Farmers Welfare, and as a consultant with John Snow India Private Limited. He is also currently the Chancellor of the National Institute of Advanced Manufacturing Technology (NIAMT), Ranchi, Jharkhand.
Dr. Balram Bhargava is an Independent Director on the Board of Molbio Diagnostics. He holds a bachelor’s degree in medicine and surgery from the University of Lucknow, a doctor of medicine degree from the University of Lucknow, and a doctor of medicine (cardiology) degree from the University of Lucknow.
He has previously served as a professor of cardiology at the All-India Institute of Medical Sciences, New Delhi, the Director General of the Indian Council of Medical Research, and Secretary, Department of Health Research, Ministry of Health and Family Welfare. He serves as a director on the board of Cipla Limited.
Nupur Garg is an Independent Director on the Board of our Company. She holds a master’s degree in business administration from Massachusetts Institute of Technology, Cambridge, USA. She has also completed a course on private equity and venture capital from Harvard Business School, Boston, USA.
She is an associate member of the Institute of Chartered Accountants of India. She has experience in the fields of finance and private equity. She serves as an independent director on the board of Kids Clinic India Limited, Kerala Infrastructure Fund Management Limited, and EAAA Real Assets Managers Limited. She previously served as advisor to Triple Jump B.V. She was also associated with Discovery Communications India, International Finance Corporation, and was an independent member of the investment committee of NIIF Fund of Funds–I managed by National Investment and Infrastructure Fund Limited.
She was awarded the ‘Business Excellence and Innovative Best Practices – Academia Award 2019’ by New Delhi Institute of Management. She was listed in the BW ‘VC World Most Influential Women 2022’, VCWorld ‘Most Influential Women 2023’, VCWorld ‘Most Influential Women 2024’, Forbes W-Power list of ‘Self-Made Women 2020’, and the Association of International Wealth Management of India’s list of ‘India’s Top 100 Women in Finance 2019’.